Jeremy Lewin

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

Jeremy Lewin, Jean‐Charles Soria, Anastasios Stathis et al. · Journal of Clinical Oncology · 2018 · 267 citations

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 172 citations

Urology, Overall Survival, Genitourinary Cancer +8

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

Johanna C. Bendell, Tae Won Kim, Boon Cher Goh et al. · Journal of Clinical Oncology · 2016 · 158 citations

Serial Biopsy Cohort, Immunology, Immunoediting +21

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial

Shankar Siva, Mathias Bressel, Simon Wood et al. · European Urology · 2021 · 132 citations

Short-course Pembrolizumab, Urology, Surgical Oncology +7